deltatrials
Not Yet Recruiting PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT07000253

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma (OMEC-5)

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma: A Randomized Prospective Clinical Study (OMEC-5)

Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions Esophageal Cancer Esophageal Carcinoma Gastric (Cardia, Body) Cancer Gastric (Stomach) Cancer Gastric Adenocarcinoma Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Interventions Chemotherapy Immunotherapy Radiotherapy Surgery Targeted Systemic Therapy
Updated 1 time since 2025 Last updated: May 29, 2025 Started: Jan 31, 2026 Primary completion: Jun 30, 2031 Completion: Jan 31, 2034
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07000253, this PHASE2/PHASE3 trial focuses on Esophageal Cancer and Esophageal Carcinoma and remains actively recruiting participants. Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), it has been updated 1 time since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jun 2025 – present · 13 months · monthly snapshotNot Yet Recruiting

Change History

1 version recorded
Not Yet Recruiting — PHASE2/PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
  • UMC Utrecht
Data source: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations